Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12326164 | 0.82 | ALDH1A1 (0.59) | CYP1A1CYP1B1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL17178271 | 0.80 | CYP1A2 (0.47) | CYP1A1CYP1B1ALDH1A1DRD1CYP3A4 | |
| SCHEMBL17174325 | 0.79 | DRD1 (0.34) | DRD1 | |
| SCHEMBL15667285 | 0.77 | DRD1 (0.55) | DRD1CRHR1 | |
| SCHEMBL22106546 | 0.75 | ALDH1A1 (0.50) | CYP1A1CYP1B1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL24393042 | 0.75 | ELANE (0.42) | CYP1A1CYP1B1ALDH1A1HPGD | |
| SCHEMBL19390560 | 0.74 | CYP3A4 (0.41) | ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL1326460 | 0.74 | CYP1A1 (0.48) | CYP1A1CYP1B1ALDH1A1CYP3A4CRHR1 | |
| SCHEMBL15696254 | 0.72 | PTGS2 (0.50) | DRD1DYRK1AMEN1KMT2AHPGD | |
| SCHEMBL15698827 | 0.72 | DRD1 (0.53) | DRD1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617275-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, ADRA1D, ADRB1 | CYP1A1 203/4885CYP1B1 280/4885ALDH1A1 1063/4885 |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, DRD3, ADRB1 | CYP1A1 742/4885CYP1B1 1135/4885ALDH1A1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.